Relmada Therapeutics (RLMD) News Today → How to automate your options trades (From DTI) (Ad) Free RLMD Stock Alerts $3.34 -0.15 (-4.30%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comRelmada Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($0.86) Per Share (NASDAQ:RLMD)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial FootingMay 10, 2024 | markets.businessinsider.comBuy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial StabilityMay 9, 2024 | finance.yahoo.comQ1 2024 Relmada Therapeutics Inc Earnings CallMay 8, 2024 | msn.comRLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024May 8, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comRelmada Therapeutics (RLMD) Set to Announce Quarterly Earnings on WednesdayRelmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 6, 2024 | prnewswire.comRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024April 23, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3% Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3%April 16, 2024 | finance.yahoo.comRELMADA THERAPEUT.DL-,001 (4E2.F)March 21, 2024 | seekingalpha.comRelmada Therapeutics: Run Up Into Results May Resume Following This DropMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial StabilityMarch 20, 2024 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comQ4 2023 Relmada Therapeutics Inc Earnings CallMarch 19, 2024 | investorplace.comRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023March 19, 2024 | benzinga.comRecap: Relmada Therapeutics Q4 EarningsMarch 19, 2024 | finance.yahoo.comRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial ResultsMarch 19, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 19, 2024March 18, 2024 | msn.comRelmada Therapeutics FY 2023 Earnings PreviewMarch 16, 2024 | finance.yahoo.comRLMD Apr 2024 2.500 putMarch 5, 2024 | prnewswire.comRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 18, 2024 | marketbeat.comSilverarc Capital Management LLC Acquires Shares of 100,000 Relmada Therapeutics, Inc. (NASDAQ:RLMD)Silverarc Capital Management LLC acquired a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company's stock,February 13, 2024 | investing.comRelmada Therapeutics Inc (RLMD)February 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)February 4, 2024 | thestreet.comRelmada Therapeutics Inc.February 2, 2024 | msn.comRelmada Therapeutics And 2 Other Penny Stocks Insiders Are BuyingFebruary 1, 2024 | marketwatch.comRelmada Therapeutics Shares Hit 52-Week High After Execs Buy SharesFebruary 1, 2024 | finance.yahoo.comRelmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 SharesJanuary 31, 2024 | marketbeat.comFY2024 Earnings Forecast for Relmada Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RLMD)Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of Relmada Therapeutics in a note issued to investors on Monday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will postJanuary 30, 2024 | benzinga.comRelmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and DatesJanuary 30, 2024 | marketbeat.comLeerink Partnrs Weighs in on Relmada Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:RLMD)Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Investment analysts at Leerink Partnrs issued their FY2028 earnings estimates for shares of Relmada Therapeutics in a research report issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will postJanuary 23, 2024 | morningstar.comRelmada Therapeutics Inc RLMDJanuary 23, 2024 | finance.yahoo.comRelmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutionsJanuary 4, 2024 | realmoney.thestreet.comMizuho sees weakness in Relmada Therapeutics shares as buying opportunityJanuary 4, 2024 | marketwatch.comRelmada Therapeutics Shares Slide as Medical Chief ExitsJanuary 4, 2024 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate UpdateDecember 30, 2023 | marketbeat.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Down 26.2% in DecemberRelmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 638,800 shares, a decrease of 26.2% from the November 30th total of 865,800 shares. Based on an average trading volume of 172,800 shares, the days-to-cover ratio is presently 3.7 days.November 10, 2023 | markets.businessinsider.comBuy Rating for Relmada Therapeutics: Efficient Management, Promising Trials and Prudent Financial ControlNovember 10, 2023 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | msn.comRelmada Therapeutics GAAP EPS of -$0.73November 8, 2023 | finance.yahoo.comRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | benzinga.comEarnings Outlook For Relmada TherapeuticsNovember 6, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Relmada Therapeutics StockNovember 3, 2023 | finance.yahoo.comRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023October 11, 2023 | finance.yahoo.comRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023October 9, 2023 | finance.yahoo.comRelmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitOctober 6, 2023 | finance.yahoo.comRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressSeptember 26, 2023 | finance.yahoo.comHere's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. RLMD Media Mentions By Week RLMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.580.42▲Average Medical News Sentiment RLMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼41▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PMV Pharmaceuticals News Adicet Bio News Citius Pharmaceuticals News Corvus Pharmaceuticals News Connect Biopharma News Cellectar Biosciences News Allakos News Rezolute News Abeona Therapeutics News Immunic News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
